Drug Trial Radar · NCT06333509
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Apr 15, 2024
Primary completion
Jun 15, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
Conditions
- Multiple Myeloma
- Primary Plasma Cell Leukemia
Interventions
CT071Biological
a single CAR-T infusion of CT071
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD).Time frame: Day 1 - Month 24
- Phase 2: Objective response rateTime frame: Day 1 - Month 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.